GPT2 mediates metabolic alterations in platinum-resistant ovarian cancer cells

Area of Science:

• Oncology
• Cancer Metabolism
• Biochemistry

Background:

• Metabolic reprogramming is a key hallmark of cancer, contributing to drug resistance.
• Ovarian cancer, a deadly gynecologic cancer, often exhibits platinum resistance, leading to poor patient survival.
• The specific metabolic mechanisms underlying platinum resistance in ovarian cancer remain poorly understood.

Purpose of the Study:

• To investigate metabolic signatures in platinum-resistant versus platinum-sensitive ovarian cancer cells.
• To identify key metabolic enzymes and pathways associated with chemoresistance.
• To evaluate glutamic-pyruvic transaminase 2 (GPT2) as a potential therapeutic target.

Main Methods:

• Comparative analysis of metabolic profiles in platinum-resistant and sensitive ovarian cancer cell lines.
• Quantification of oxidative phosphorylation (OXPHOS), glutaminolysis, and tricarboxylic acid (TCA) cycle metabolites.
• Gene expression analysis of key metabolic enzymes, including GPT2.
• GPT2 gene knockout experiments in chemoresistant cells.

Main Results:

• Chemoresistant ovarian cancer cells exhibit significantly increased oxidative phosphorylation (OXPHOS) compared to chemosensitive cells.
• Elevated glutaminolysis and TCA cycle metabolites support the enhanced OXPHOS in resistant cells.
• The enzyme glutamic-pyruvic transaminase 2 (GPT2) was upregulated in chemoresistant cells and associated with poor patient prognosis.
• GPT2 knockout reversed the metabolic phenotype and restored platinum sensitivity in chemoresistant cells.

Conclusions:

• GPT2 is a critical mediator linking glutaminolysis, the TCA cycle, and OXPHOS in chemoresistant ovarian cancer.
• Targeting GPT2 holds potential for overcoming platinum resistance by modulating cancer cell metabolism.
• These findings provide a translational basis for developing GPT2-targeted therapies for ovarian cancer patients.